Macrogenics (MGNX) Equity Average (2013 - 2026)

Macrogenics (MGNX) has 14 years of Equity Average data on file, last reported at $38.4 million in Q1 2026.

• Equity Average for Q1 2026 came in at $38.4 million, down 60.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.4 million (down 60.66% YoY), and the FY2025 annual result was $85.8 million, down 36.11% from the prior year.
• Equity Average retreated to $38.4 million in Q1 2026 per MGNX's latest filing, from $61.3 million in the prior quarter.
• Over five years, Equity Average peaked at $208.9 million in Q1 2022 and troughed at $38.4 million in Q1 2026.
• A 5-year average of $117.2 million and a median of $125.6 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2026: Equity Average soared 37.71% in 2023, then tumbled 60.66% in 2026.
• A 5-year view of Equity Average shows it stood at $132.5 million in 2022, then soared by 30.8% to $173.3 million in 2023, then plunged by 31.87% to $118.1 million in 2024, then sank by 48.08% to $61.3 million in 2025, then sank by 37.36% to $38.4 million in 2026.
• Business Quant data shows MGNX's Equity Average at $38.4 million in Q1 2026, $61.3 million in Q4 2025, and $56.8 million in Q3 2025.